Molecular profiling and personalised treatment concepts in advanced non-small cell lung cancer: pertinent clinical dilemmas

Symposium
Chairs: J. Cadranel (Paris Cedex 20, France), M. Skrzypski (Sopot, Poland)
Aims: to describe problems relating to the fact that basic and clinical research improves molecular profiling and personalised treatment concepts in non-small cell lung cancer (NSCLC) at a rapid pace that is hard to keep up with in routine care; to discuss possible solutions

Re-biopsy or liquid biopsy for molecular diagnosis of resistance mutations in the era of third-generation targeted therapies S. Janes (London, United Kingdom)
Concomitant versus sequential third-generation targeted therapies in advanced epidermal growth factor receptor- or anaplastic lymphoma kinase-positive NSCLC J. Cadranel (Paris Cedex 20, France)
Next-generation sequencing and assessment of tumour mutational burden: are these tools ready for clinical routine use? L. Hendriks (Maastricht, Netherlands)
Monoimmunotherapy for a happy few or combination immunotherapy for all: when to stop and how to proceed R. Huber (Munich, Germany)